Pralsetinib in the treatment of pleomorphic xanthoastrocytoma with RET‑activated: A case report
Rearranged during transfection (RET)‑activated gliomas are exceptionally rare and associated with a poor prognosis, and there are no established effective therapies. Clinical data on RET inhibitors are predominantly derived from solid tumors such as non‑small cell lung cancer and medullary thyroid carcinoma, with data for central nervous system tumors being scarce. The present report describes a case of pleomorphic xanthoastrocytoma with RET activation that progressed following the Stupp regimen but subsequently exhibited a favorable response to pralsetinib, teniposide and bevacizumab. The tumor area decreased from 4.84 cm2 before treatment to 1.92 cm2 (calculated based on the longest and maximum perpendicular diameters).
Authors
- ShiZhen Zhou
- Rongjie Tao
- XueQiang Pan
- Yueliang Zheng
- Peng Sun
- Yan Li
- Huayang Zhao
- Hui Wang
Publication Details
- Journal
- Experimental and Therapeutic Medicine
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3892/etm.2026.13364
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00